We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$337M
Cap. Flow %
-21.88%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 10.49%
2 Financials 0.07%
3 Technology 0.07%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
176
PUT
Bristol-Myers Squibb
BMY
$130B
$278K 0.02%
+60
New +$2.63K
DNDN
177
DELISTED
DENDREON CORPORATION
DNDN
$263K 0.02%
+89,800
New +$332K
ARWR icon
178
CALL
Arrowhead Research
ARWR
$12.1B
$250K 0.02%
+439
New +$1.69K
CASC
179
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$230K 0.01%
+186
New +$1.96K
TLPH icon
180
CALL
Talphera
TLPH
$67.5M
$215K 0.01%
+10
New +$2.18K
ARAY icon
181
CALL
Accuray
ARAY
$29M
$188K 0.01%
+254
New +$1.6K
ECYT
182
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
$143K 0.01%
+107
New +$1.69K
SEEL
183
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
AGEN
184
CALL
Agenus
AGEN
$275M
$96K 0.01%
+18
New +$1.23K
CCXI
185
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$86K 0.01%
+155
New +$1.68K
SQNM
186
CALL
DELISTED
SEQUENOM INC NEW
SQNM
$78K 0.01%
+293
New +$984
SQNM
187
PUT
DELISTED
SEQUENOM INC NEW
SQNM
$55K ﹤0.01%
+205
New +$689
TENX icon
188
Tenax Therapeutics
TENX
$419M
$54K ﹤0.01%
+1
New +$59K
SQNM
189
DELISTED
SEQUENOM INC NEW
SQNM
$41K ﹤0.01%
+15,400
New +$51.7K
ATHX
190
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$40K ﹤0.01%
+10
New +$425
CYTR
191
CALL
DELISTED
CytRx Corp
CYTR
$40K ﹤0.01%
+21
New +$310
ONCY
192
CALL
DELISTED
ONCOLYTICS BIOTECH INC
ONCY
$24K ﹤0.01%
+100
New +$277
ATHX
193
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$22K ﹤0.01%
+5
New +$212
ABBV icon
194
CALL
AbbVie
ABBV
$465B
– –
-2,926
Closed -$12.1M
ABBV icon
195
AbbVie
ABBV
$465B
– –
-355,626
Closed -$14.7M
ABBV icon
196
PUT
AbbVie
ABBV
$465B
– –
-9,253
Closed -$38.3M
ALGN icon
197
CALL
Align Technology
ALGN
$12.6B
– –
-889
Closed -$3.29M
ALNY icon
198
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
– –
-468
Closed -$1.45M
ARWR icon
199
Arrowhead Research
ARWR
$12.1B
– –
-2,276,980
Closed -$8.75M
ASMB icon
200
Assembly Biosciences
ASMB
$507M
– –
-11,590
Closed -$1.67M
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management withdrew a net $337M in Q3 2013, closing 65 positions and reducing 41 holdings. Its most notable exit was AbbVie, an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 11% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Tompkins Financial worth $1.02M.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.